Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SPTLC2 | O15270 | 5/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 3/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20262220 | 0.83 | RORC (0.44) | SPTLC2EPHX2KDM1AMAOAMAOB | |
| SCHEMBL4156476 | 0.76 | NOTUM (0.43) | NOTUMSPRADAMTS5 | |
| SCHEMBL4156475 | 0.76 | NOTUM (0.43) | NOTUMSPRADAMTS5 | |
| SCHEMBL1972533 | 0.75 | TLR2 (0.43) | KDM1AMAOAMAOB | |
| SCHEMBL1969431 | 0.75 | TLR2 (0.43) | KDM1AMAOAMAOB | |
| SCHEMBL4157819 | 0.75 | RHOC (0.43) | SPTLC2KCNH2CACNA1I | |
| SCHEMBL4157818 | 0.75 | RHOC (0.43) | SPTLC2KCNH2CACNA1I | |
| SCHEMBL1969992 | 0.73 | TACR1 (0.44) | CYP2D6 | |
| SCHEMBL2247004 | 0.73 | FPR1 (0.45) | EPHX2KDM1AMAOAMAOB | |
| SCHEMBL1971251 | 0.72 | SLC6A4 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | STS 2213/4885NOTUM 2970/4885SPTLC2 4574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.